Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

 Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Co-Founder, COO, CBO, Platelet BioGenesis
Sven Karlsson, CFA, MBA, is co-founder, chief operating officer, and chief business officer of Platelet BioGenesis, the only company in the world manufacturing functional human platelets. At PBG, he has grown the company from one employee to 25, raised more than $20 million in venture capital and non-dilutive grants, and advanced the company’s scalable, cGMP-compliant platelet bioreactor. PBG is developing a platelet platform to create an entirely new class of therapeutics: designer platelets to treat cancer and other life-threatening diseases. The company plans to enter the clinic with its first product, donor-independent platelets for transfusion, in 2021. Earlier in his career, Karlsson held a variety of board-level and senior positions in the renewable energy field, helping a variety of green energy startups raise their first financing rounds, find their first customers, and scale to profitability. Karlsson started his career as a senior analyst for M&A and business development at JPMorgan and also held positions at a number of asset management firms.

Brought to you by